Finanzen von Maia Biotechnology Inc (MAIA)MAIAMaia Biotechnology Inc

Evaluating the bottom line, Maia Biotechnology Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -218.68%, provide a clear picture of how effectively MAIA converts its operational activities into shareholder value.

In the context of the broader market, MAIA competes directly with industry leaders such as GANX and OSTX. With a market capitalization of $83.95M, it holds a significant position in the sector. When comparing efficiency, MAIA's gross margin of N/A stands against GANX's N/A and OSTX's N/A. Such benchmarking helps identify whether Maia Biotechnology Inc is trading at a premium or discount relative to its financial performance.

The company has shown significant financial losses, with net income reaching -7943587 USD in Q2 2026 and an EPS of -0.13. The current ratio is strong at 4.51, indicating good short-term financial health, but the overall profitability remains a concern.